Literature DB >> 11273778

Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells.

R E Donahue1, B P Sorrentino, R G Hawley, D S An, I S Chen, R P Wersto.   

Abstract

The fibronectin fragment CH-296 improved gene transfer to cytokine-mobilized nonhuman primate CD34+ cells irrespective of tropism to the MoMLV, GaLV, and VSV-G envelope proteins using murine stem cell virus (MSCV) and human immunodeficiency virus-1 (HIV-1)-based retrovirus vectors. For the HIV-1 lentivirus vector, CH-296 enhanced gene transfer in the absence of added hematopoietic growth factors necessary for ex vivo stem cell expansion. In the presence of CH-296, apoptosis of CD34+ cells was inhibited, and in mobilized peripheral blood CD34+ cells, cell division was stimulated as measured by cell history/tracking experiments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273778     DOI: 10.1006/mthe.2001.0269

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

Review 1.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  In vitro culture during retroviral transduction improves thymic repopulation and output after total body irradiation and autologous peripheral blood progenitor cell transplantation in rhesus macaques.

Authors:  Karin Loré; Ruth Seggewiss; F Javier Guenaga; Stefania Pittaluga; Robert E Donahue; Allen Krouse; Mark E Metzger; Richard A Koup; Cavan Reilly; Daniel C Douek; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2006-02-23       Impact factor: 6.277

Review 3.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

4.  Reducing the genotoxic potential of retroviral vectors.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2008

5.  Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin.

Authors:  Lijing Li; Mónica Torres-Coronado; Angel Gu; Anitha Rao; Agnes M Gardner; Elizabeth W Epps; Nancy Gonzalez; Chy-Anh Tran; Xiwei Wu; Jin-Hui Wang; David L DiGiusto
Journal:  Stem Cells Transl Med       Date:  2014-08-08       Impact factor: 6.940

6.  Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Authors:  Peter Ebeling; P Bach; U Sorg; A Schneider; T Trarbach; D Dilloo; H Hanenberg; S Niesert; S Seeber; T Moritz; M Flasshove
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-20       Impact factor: 4.553

Review 7.  Large animal models of hematopoietic stem cell gene therapy.

Authors:  G D Trobridge; H-P Kiem
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

8.  Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus.

Authors:  Christoph A Kahl; Jon Marsh; Joanne Fyffe; David A Sanders; Kenneth Cornetta
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  RECQL5 cooperates with Topoisomerase II alpha in DNA decatenation and cell cycle progression.

Authors:  Mahesh Ramamoorthy; Takashi Tadokoro; Ivana Rybanska; Avik K Ghosh; Robert Wersto; Alfred May; Tomasz Kulikowicz; Peter Sykora; Deborah L Croteau; Vilhelm A Bohr
Journal:  Nucleic Acids Res       Date:  2011-10-19       Impact factor: 16.971

Review 10.  Large animal models for foamy virus vector gene therapy.

Authors:  Grant D Trobridge; Peter A Horn; Brian C Beard; Hans-Peter Kiem
Journal:  Viruses       Date:  2012-12-07       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.